First personalised cancer vaccine cuts risk of disease returning in major trial
0 / 31
English
中文
Tony Chapman, 75, from Corby in the East Midlands was one of the 1,100 melanoma patients enrolled on the vaccine trial A new personalised cancer vaccine given alongside a widely used immunotherapy drug has cut the risk of patients dying or their skin cancer returning by 42% in a major clinical trial.
（暂无翻译）
The researchers involved say the results could mark a turning point in cancer treatment, bringing personalised medicine a step closer.
（暂无翻译）
The trial also found that the new drug combination reduced the risk of melanoma, a type of skin cancer, spreading by 38% over two years compared to immunotherapy alone.
（暂无翻译）
The drug manufacturers MSD and Moderna say the same approach is already being tested against other tumours, including kidney, bladder and lung cancer.
（暂无翻译）
Independent cancer experts described the results as impressive but said longer-term studies were still needed to establish whether the treatment really helps most patients live longer, on average.
（暂无翻译）
The new approach is aimed at cancer patients who have already had their tumour removed through surgery.
（暂无翻译）
In the trial, 1,137 adults were given Keytruda, an established immunotherapy drug which helps the body's immune system find and attack cancer cells.
（暂无翻译）
About two-thirds also received an experimental vaccine with the rest being given a placebo or dummy drug.
（暂无翻译）
The vaccine, called Intismeran, uses the same mRNA technology as some Covid jabs.
（暂无翻译）
It is personalised to each patient, using information from their own tumour to help train their immune system to recognise cancer cells and target them if they return.
（暂无翻译）
Two years after starting the treatment, the patients who received the jab were far less likely to have had melanoma come back or see it spread across the body.
（暂无翻译）
"Personalisation is the next step up and it's really exciting, it's a fabulous technology," says Prof Pippa Corrie, a consultant medical oncologist who helped run part of the study with patients at Addenbrooke's Hospital in Cambridge.
（暂无翻译）
"The question is how much can we really demonstrate it's worth and this trial was the first proof of principle."
（暂无翻译）
The latest checks show that Tony Chapman is cancer free three years after he was first told melanoma skin cancer had spread to his lymph nodes Prof Corrie worked with patients enrolled in the trial including 75-year old Tony Chapman, who was diagnosed with melanoma in 2019.
（暂无翻译）
He had the tumour removed from his chest but a lump later appeared under his arm.
（暂无翻译）
He was told his cancer had returned and he needed a second operation.
（暂无翻译）
He then volunteered to take part in the study but, like all the other participants, he still doesn't know whether he was given the experimental vaccine or a placebo alongside his immunotherapy treatment. "This just seemed like a really good example of moving science forward, as well as getting some benefit for yourself, so what's to lose?" Tony said.
（暂无翻译） （暂无翻译）
Three years on he is now having checks every six months and remains cancer-free.
（暂无翻译）
Shares in the drugmakers MSD (known as Merck in the US) and Moderna have surged since both companies first hinted at the success of the vaccine in the summer.
（暂无翻译）
But investors sold off stock on Thursday after financial analysts said the results were not quite as strong as those seen in an earlier, much smaller trial.
（暂无翻译）
Both companies said they were now "engaging with authorities" suggesting they could file for approval from medicine regulators as soon as next year.
（暂无翻译）
Widespread NHS use will also depend on cost, given that each individual patient will need to have their tumour genetically analysed and a personalised vaccine made for them.
（暂无翻译）
The trial will continue so that the patients involved can be monitored – both to see if the cancer returns over time and to assess whether the drug ultimately helps them live longer.
（暂无翻译）
Professor Alan Melcher from the Institute of Cancer Research in London, who wasn't involved in the research, described the results as "very impressive".
（暂无翻译）
"It is an important proof of principle for the field, although we shouldn't get ahead of the evidence," he said.
（暂无翻译）
"We can't assume from one melanoma trial that the same approach will work across all cancers, and longer follow-up will be important to understand the effect on overall survival."
（暂无翻译）
The full trial results are due to be presented at a cancer conference in Madrid on Saturday.
（暂无翻译）
They have yet to be published in a peer-reviewed medical journal, where they can be scrutinised by independent experts.
（暂无翻译）
Vaccine breakthrough stops cancer returning in trial First personalised jab for skin cancer in UK trial Thousands of cancer patients to trial personalised vaccines Get our flagship newsletter with all the headlines you need to start the day.
（暂无翻译）
Sign up here.
（暂无翻译）
仅供学习使用，如有侵权请联系删除 · 查看原文